Comparative Pharmacology
Head-to-head clinical analysis: KEPPRA XR versus NEURAMATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEPPRA XR versus NEURAMATE.
KEPPRA XR vs NEURAMATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal excitability.
NEURAMATE is a brand name for pentobarbital, a barbiturate that enhances GABA-A receptor activity by binding to the barbiturate binding site, increasing the duration of chloride ion channel opening, thereby producing CNS depression.
1500 mg orally once daily (2 tablets of 750 mg). Extended-release formulation is taken once daily; immediate-release is dosed twice daily.
250 mg orally three times daily; maximum 1000 mg/day.
None Documented
None Documented
7.1 ± 1.1 hours in adults; 10–11 hours in elderly; prolonged in renal impairment (up to 25 hours in severe renal failure).
6-8 hours (normal renal function); prolonged to 12-20 hours in moderate renal impairment.
Renal: 66% as unchanged drug; 27% as inactive metabolite (uch L057); biliary/fecal: negligible (<1%).
Primarily renal (90% unchanged) with 10% biliary/fecal.
Category C
Category C
Antiepileptic
Antiepileptic